Key information

🔎 Fund Overview

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. It focuses on advancing two investigational compounds in clinical trials for patients with cancer. The Company’s product engine includes its proprietary small molecule microarray (SMM) screening platform, which provides the capability to map and target transcription regulatory networks (TRNs) in a differentiated manner to enable discovery of novel compounds and improve its ability to discover and optimize clinical development candidates. Its pipeline includes KB-0742 and Lanraplenib. KB-0742 is an oral cyclin dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. Lanraplenib is a small molecule selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML).